0.01
+0.0013(+13.00%)
Currency In USD
| Previous Close | 0.01 |
| Open | 0.01 |
| Day High | 0.01 |
| Day Low | 0.01 |
| 52-Week High | 6 |
| 52-Week Low | 0.01 |
| Volume | 199,410 |
| Average Volume | 365,486 |
| Market Cap | 380,909 |
| PE | 0 |
| EPS | 323.08 |
| Moving Average 50 Days | 0.03 |
| Moving Average 200 Days | 0.32 |
| Change | 0 |
If you invested $1000 in Windtree Therapeutics, Inc. (WINT) 10 years ago, it would be worth $0 as of February 15, 2026 at a share price of $0.011. Whereas If you bought $1000 worth of Windtree Therapeutics, Inc. (WINT) shares 5 years ago, it would be worth $0 as of February 15, 2026 at a share price of $0.011.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Windtree Therapeutics Announces the Sale of its Cardiovascular Biotech Pipeline Drug Candidates
GlobeNewswire Inc.
Dec 23, 2025 2:00 PM GMT
Seismic Pharmaceutical Holdings, LLC acquires the cardiovascular assets and will pay Windtree 20% of any milestone payments, royalty payments or similar economic interests (including all global commercial net revenues) Windtree would receive a payme
Windtree Therapeutics Announces It Has Signed a Letter of Intent to Acquire CommLoan, Inc. a Revenue Generating Company in the Rapidly Growing Fintech Space
GlobeNewswire Inc.
Dec 03, 2025 2:00 PM GMT
Windtree is executing its corporate strategy to diversify its business with revenue and profit generating divisions CommLoan, Inc. is a tech company focused on transforming the way middle market loans are originated CommLoan has streamlined the proc
Windtree Therapeutics Announces It May Receive License Agreement Payments from Its Licensee for Renewed Acute Pulmonary Development by the Licensee
GlobeNewswire Inc.
Nov 17, 2025 2:00 PM GMT
The Company has a global license agreement for the acute pulmonary that could pay up to $78.9 million in development, regulatory and commercial milestones plus low double digit royalties The licensed treatments include SURFAXIN®, lyophilized lucinact